Search Results
HER2DX risk-score in early-stage HER2-positive breast cancer
Independent validation of the HER2DX genomic test in HER2-positive breast cancer
HER2DX: a new diagnostic tool for early-stage HER2 positive breast cancer
Optimizing treatment in patients with early-stage HER2-positive breast cancer
N9831 trial: genes associated with early and late recurrence in HER2+ breast cancer
Early-Stage HER2+ Breast Cancer: The ATEMPT Trial
HER2DX and pCR in HER2-positive breast cancer: a combined analysis of 4 neoadjuvant studies
Depu Tripathy on Lower Risk for Recurrence of Early Stage Breast Cancer
Did you know that HER2-positive breast cancer accounts for up to 15-20% of all breast cancers?
Dr. Charles Perou | Distinguished Lectureship in Breast Cancer Research | SABCS 2022
Sequencing Treatment Options in HER2 Positive Breast Cancer: 2023 Best of Breast Conference
Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast Cancer
